Abstract: A formulation includes one or more active ingredients of poor water solubility for medical or non-medical use in the rearing of animals. The formulation is suitable for administration to the animals via their drinking water. It exhibits superior stability. The formulation comprises an active ingredient, a thickener combination and water, wherein the thickener combination comprises at least one thickener selected from the following groups A, B, C and D: (A) cellulose derivatives, such as methyl cellulose, sodium carboxy methyl cellulose, (B) non-cellulosic polysaccharide thickeners such as xanthan gums, Arabic gum, (C) cross-linked polyacrylic acid polymers, (D) hydrocolloidal hydrated silicates.

Abstract: The present invention concerns preferably surfactant-free solid pharmaceutical formulations comprising, as an active ingredient, at least one of irbesartan and pharmaceutically acceptable salts thereof, and at least one disintegrant. Preferably, the active ingredient comprises irbesartan hydrochloride. Also, the present invention is directed to a process for the manufacture of such formulations, including a wet granulation process (A) and a direct granulation process (B).

Abstract: The invention provides a process for the preparation of a sartan derivative of formula (I) (formula as filed in paper form) (I) wherein the substituents have the meaning indicated in the description, or a pharmaceutically acceptable salt thereof, comprising reacting 2-cyanophenylboronic acid or a derivative thereof with a p-halobenzyl-1H-imidazole derivative of formula (VI), (formula as filed in paper form) (VI) wherein (part of formula as filed in paper form), X, Y, R1 and R2 are as defined above, and Z is I, Br or Cl, in the presence of a transition metal catalyst and an inorganic or organic base. The invention also provides new intermediates of formula (V), (formula as filed in paper form) (V) wherein M is an alkali metal or an NR4R5R6R7 group; and of formula (II) (formula as filed in paper form) (II).

Abstract: The invention relates to a process for the preparation of form I of olanzapine, crystallized from a solvent mixture which comprises 2-propanol, some pseudopolymorphic forms, namely solvates of olanzapine, a new polymorphic form A of olanzapine, and processes for the preparation thereof.

Abstract: The invention provides a process for the preparation of a sartan derivative of formula (I) (formula as filed in paper form) (I) wherein the substituents have the meaning indicated in the description, or a pharmaceutically acceptable salt thereof, comprising reacting 2-cyanophenylboronic acid or a derivative thereof with a p-halobenzyl-1H-imidazole derivative of formula (VI), (formula as filed in paper form) (VI) wherein (part of formula as filed in paper form), X, Y, R1 and R2 are as defined above, and Z is I, Br or Cl, in the presence of a transition metal catalyst and an inorganic or organic base.